Chlorpheniramine / ibuprofen / phenylephrine and Alcohol/Food Interactions
There are 3 alcohol/food/lifestyle interactions with chlorpheniramine / ibuprofen / phenylephrine which include:
Moderate Food Interaction
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
- Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):
- "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.
- Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
- "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.
High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
NSAIDs - fluid retention
Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
- Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A "NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics." Arch Intern Med 158 (1998): 1108-12
- "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- Lewis RV, Toner JM, Jackson PR, Ramsay LE "Effects of indomethacin and sulindac on blood pressure of hypertensive patients." Br Med J 292 (1986): 934-5
- Johnson AG, Nguyen TV, Day RO "Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis." Ann Intern Med 121 (1994): 289-300
- "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
- "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
- "Product Information. Anaprox (naproxen)." Roche Laboratories, Nutley, NJ.
- "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
- "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
- "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
- Agnholt J, Andreasen F "The effect of ibuprofen therapy on water and electrolyte balance." Acta Med Scand 212 (1982): 65-9
- "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
- Gurwitz JH, Everitt DE, Monane M, et al "The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons." J Gerontol A Biol Sci Med Sci 51 (1996): m74-9
- "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
- Heynen G "Toleration and safety of piroxicam." Eur J Rheumatol Inflamm 8 (1987): 86-93
- "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
- Easton PA, Koval A "Hypertensive reaction with sulindac." Can Med Assoc J 122 (1980): 1273-4
- Brooks CD, Linet OI, Schellenberg D, Turner LF, Defesche CL, Teoh KW, Johnson JH, Assenzo JR "Clinical safety of flurbiprofen." J Clin Pharmacol 30 (1990): 342-51
- Petersson I, Nilsson G, Hansson B-G, Hedner T "Water intoxication associated with non-steroidal anti-inflammatory drug therapy." Acta Med Scand 221 (1987): 221-3
- "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
- "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
- Van Den Ouweland FA, Gribnau FW, Meyboom RH "Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly." Age Ageing 17 (1988): 8-16
- "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
- Buckley MM, Brogden RN "Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 39 (1990): 86-109
- Willkens RF "Worldwide clinical safety experience with diclofenac." Semin Arthritis Rheum 2 Suppl 1 (1985): 105-10
- "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
- "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
NSAIDs - hypertension
NSAIDs including topicals can lead to the onset of new hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. Blood pressure should be monitored closely during NSAID therapy and throughout the course of therapy.
Chlorpheniramine / ibuprofen / phenylephrine drug interactions
There are 762 drug interactions with chlorpheniramine / ibuprofen / phenylephrine
Chlorpheniramine / ibuprofen / phenylephrine disease interactions
There are 21 disease interactions with chlorpheniramine / ibuprofen / phenylephrine which include:
- fluid retention
- GI toxicity
- renal toxicities
- cardiovascular disease
- anticholinergic effects
- renal/liver disease
- heart failure
- platelet aggregation inhibition
More about chlorpheniramine / ibuprofen / phenylephrine
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|